PT  - JOURNAL ARTICLE
AU  - Gentile, Juliana E
AU  - Heiss, Christina
AU  - Corridon, Taylor L
AU  - Mortberg, Meredith A
AU  - Fruhwürth, Stefanie
AU  - Guzman, Kenia
AU  - Grötschel, Lana
AU  - Chan, Kwan
AU  - Herring, Neil C
AU  - Janicki, Timothy
AU  - Nhass, Rajaa
AU  - Sarathy, Janani Manavala
AU  - Erickson, Brian
AU  - Kunz, Ryan
AU  - Erickson, Alison
AU  - Braun, Craig
AU  - Henry, Katherine T
AU  - Bry, Lynn
AU  - Arnold, Steven E
AU  - Minikel, Eric Vallabh
AU  - Zetterberg, Henrik
AU  - Vallabh, Sonia M
TI  - Evidence that minocycline treatment confounds the interpretation of neurofilament as a biomarker
AID  - 10.1101/2024.05.01.24306384
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.05.01.24306384
4099  - http://medrxiv.org/content/early/2024/05/02/2024.05.01.24306384.short
4100  - http://medrxiv.org/content/early/2024/05/02/2024.05.01.24306384.full
AB  - Neurofilament light (NfL) concentration in cerebrospinal fluid (CSF) and blood serves as an important biomarker in neurology drug development. Changes in NfL are generally assumed to reflect changes in neuronal damage, while little is known about the clearance of NfL from biofluids. We observed an NfL increase of 3.5-fold in plasma and 5.7-fold in CSF in an asymptomatic individual at risk for genetic prion disease following 6 weeks’ treatment with oral minocycline for a dermatologic indication. Other biomarkers remained normal, and proteomic analysis of CSF revealed that the spike was exquisitely specific to neurofilaments. NfL dropped nearly to normal levels 5 weeks after minocycline cessation, and the individual remained free of disease 2 years later. Plasma NfL in dermatology patients was not elevated above normal controls. Dramatically high plasma NfL (>500 pg/mL) was variably observed in some hospitalized individuals receiving minocycline. In mice, treatment with minocycline resulted in variable increases of 1.3- to 4.0-fold in plasma NfL, with complete washout 2 weeks after cessation. In neuron-microglia co-cultures, minocycline increased NfL concentration in conditioned media by 3.0-fold without any visually obvious impact on neuronal health. We hypothesize that minocycline does not cause or exacerbate neuronal damage, but instead impacts the clearance of NfL from biofluids, a potential confounder for interpretation of this biomarker.Competing Interest StatementBE, RK, AE, CB are employees of IQ Proteomics. KTH is an employee of Charles River Laboratories. SEA acknowledges speaking fees from Abbvie, Biogen, EIP Pharma, Roche, and Sironax; consulting fees from Athira, Biogen, Cassava, Cognito, Cortexyme, Sironax, and vTv; research support from Abbvie, Amylyx, EIP Pharma, and Merck. EVM acknowledges speaking fees from Eli Lilly; consulting fees from Deerfield and Alnylam; research support from Ionis, Gate, Sangamo, Eli Lilly. HZ is co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg.SMV acknowledges speaking fees from Ultragenyx, Illumina, Biogen, Eli Lilly; consulting fees from Invitae and Alnylam; research support from Ionis, Gate, Sangamo, Eli Lilly.Funding StatementWe thank all research participants for their contributions to this study. This work was funded by Prion Alliance, the Broad Institute (BroadIgnite Accelerator), donations to the Prions@Broad fund, and the National Institutes of Health (R21 TR003040, R01 NS125255, R01 NS132022).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human samples were collected through Mass General Brigham (MGB) Institutional Review Board (IRB) protocols 2015P000221, 2017P000214, and 2021P002185. Our prion cohort research participant provided written informed consent. Discarded plasma samples were collected under a waiver of consent approved by the MGB IRB.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesSource code and an analytical dataset sufficient to reproduce all figures and statistics in this manuscript will be made publicly available at https://github.com/ericminikel/mino https://github.com/ericminikel/mino